Omicron News and Research

RSS

The human antibody response to the SARS-CoV-2 spike protein N-terminal domain in a group of previously infected individuals

Researchers evaluated the human antibody response to the NTD of the S protein by investigating a group of individuals who had previously been infected with SARS-CoV-2 or who had received an mRNA vaccine.

11 Apr 2022

New research on SARS-CoV-2 Omicron variant mutations and sotrovimab therapy

A recent study posted to the medRxiv* preprint server assessed the impact of sotrovimab treatment on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant-infected immunocompromised (IC) patients.

11 Apr 2022

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

In a recent study posted to the bioRxiv* preprint server, researchers developed aminoadamantane nitrates compounds that inhibit the ion channels formed by the envelope (E) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and enable targeted drug delivery of nitric oxide (NO)-related group for S-nitrosylation of host angiotensin-converting enzyme 2 (ACE2), which would inhibit ACE2 binding with the viral spike (S) protein and thereby inhibit viral replication in the host.

11 Apr 2022

Immunocompromised hosts with Delta/Omicron co-infections

A recent study posted to the medRxiv* preprint server examined clinical cases of co-infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta/Omicron variants and Omicron BA.1/ BA.2 sublineages in immunocompromised (IC) patients.

10 Apr 2022

A novel PLpro inhibitor as a broad-spectrum anti-coronavirus agent

Researchers identify a potentially effective compound against COVID-19 against the SARS-CoV-2 PLpro.

10 Apr 2022

CDC report on Omicron infections soon after Delta

A new study identifies ten patients with confirmed SARS-CoV-2 Omicron variant infections within 90 days of a previous Delta variant infection.

10 Apr 2022

Substantial SARS-CoV-2 infection in perivascular cells of inflamed blood vessels

A new study demonstrated that vascular inflammation leads to heightened SARS-CoV-2 infection in perivascular cells.

8 Apr 2022

Study explores the antibody evasion pattern of SARS-CoV-2 Omicron sublineages

...

8 Apr 2022

SARS-CoV-2 Omicron variant spike-specific unique cluster of differentiation cells

A new study presented a safe and efficient multi-epitope SARS-CoV-2 vaccine construct against SARS-CoV-2 variants, including Omicron.

8 Apr 2022

SARS-CoV-2 Delta-Omicron recombinant identified in a transplant patient treated with Sotrovimab

Researchers described a case of co-infection with SARS-CoV-2 variants of concern, Delta and Omicron.

8 Apr 2022

Study characterizes SARS-CoV-2 spike-specific cluster of differentiation 4+ T-cell response

In a new study, researchers characterized over 100 SARS-CoV-2-specific CD4+ T-cell epitopes.

8 Apr 2022

Improved seroprevalence and antibody response after third COVID-19 vaccination

Researchers evaluated the immunogenicity of a third COVID-19 vaccination in antibody deficient subjects.

8 Apr 2022

Neutralization potency against the Omicron variant of naturally expressed MBC-derived IgG antibodies from vaccinated individuals

Researchers have shown how the Omicron variant of the SARS-CoV-2 successfully evaded a large fraction of antibodies derived from memory B cells, giving rise to a reduced, but incomplete immune escape.

8 Apr 2022

Study on the viral dynamics of Omicron and Delta infected individuals

Researchers examine the infectious periods in vaccinated individuals infected with the SARS-CoV-2 Omicron and Delta variants.

7 Apr 2022

SARS-CoV-2 mutations capable of widespread T-cell escape

A new study aimed to identify and screen the mutations observed in SARS-CoV-2 that help to facilitate CD8+ T-cell escape.

7 Apr 2022

Researchers reveal why people with allergic asthma are protected from severe COVID

The vast majority of people infected with the omicron variant of SARS-CoV-2 experience mild cold-like symptoms, moderate flu-like symptoms, or no symptoms at all, but the virus is so transmissible that it still spread deep into lung tissue to cause severe disease and death in thousands of people in the United States in 2022 alone.

7 Apr 2022

Omicron News and Research

The human antibody response to the SARS-CoV-2 spike protein N-terminal domain in a group of previously infected individuals

New research on SARS-CoV-2 Omicron variant mutations and sotrovimab therapy

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

Immunocompromised hosts with Delta/Omicron co-infections

A novel PLpro inhibitor as a broad-spectrum anti-coronavirus agent

CDC report on Omicron infections soon after Delta

Substantial SARS-CoV-2 infection in perivascular cells of inflamed blood vessels

Study explores the antibody evasion pattern of SARS-CoV-2 Omicron sublineages

SARS-CoV-2 Omicron variant spike-specific unique cluster of differentiation cells

SARS-CoV-2 Delta-Omicron recombinant identified in a transplant patient treated with Sotrovimab

Study characterizes SARS-CoV-2 spike-specific cluster of differentiation 4+ T-cell response

Improved seroprevalence and antibody response after third COVID-19 vaccination

Neutralization potency against the Omicron variant of naturally expressed MBC-derived IgG antibodies from vaccinated individuals

Study on the viral dynamics of Omicron and Delta infected individuals

SARS-CoV-2 mutations capable of widespread T-cell escape

Researchers reveal why people with allergic asthma are protected from severe COVID

The dynamics of the Omicron wave in England

Study investigates changing patterns of SARS-CoV-2 infection through Delta and Omicron waves

Sotrovimab found to prevent hospitalization and mortality in COVID-19 outpatients

Insights into the pathogenesis of the previous and circulating SARS-CoV-2 variants in mice

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News